论文部分内容阅读
日本的胃癌早期诊断和手术治疗已取得显著进步,5年存活率已达95%以上。但另一方面尚不能控制不适于手术的进行性胃癌的发展,故胃癌仍然占恶性肿瘤死因的首位,医生在日常诊疗中遇到不能手术的进行性胃癌的机会是很多的,因此,化疗的作用就变得重要起来。日本胃癌化疗有5氟尿嘧啶(5-FU)及氟尿嘧啶衍生物和丝裂霉素(MMC)二者,还有再加上阿霉素(ADM)三者长期并用的,但其疗效决非令人满意。可是在其后,试用了UFT及5′DFUR新型氟化嘧啶诱导物与顺氨铂(CDDP)、鬼臼乙叉甙(etoposide)、ACNU并用,更有导入5-FU生化调节等各种治疗方法,结果使有效率得到改善。
Japan’s early diagnosis of gastric cancer and surgical treatment have made significant progress. The 5-year survival rate has reached more than 95%. However, on the other hand, it is still not possible to control the development of progressive gastric cancer that is not suitable for surgery. Therefore, gastric cancer still occupies the top of the cause of death from malignant tumors. There are many opportunities for doctors to encounter inoperable progressive gastric cancer in daily medical treatment. Therefore, chemotherapy The role becomes important. Japanese gastric cancer chemotherapy has 5-fluorouracil (5-FU) and both fluorouracil derivatives and mitomycin (MMC), plus long-term combined use of doxorubicin (ADM), but its efficacy is by no means satisfaction. However, UFT and 5’DFUR novel fluoropyrimidine inducers were tried in combination with cisplatin (CDDP), etoposide, and ACNU, and various treatments such as biochemical regulation of 5-FU were introduced. The method results in improved efficiency.